4Alberts SR, Cervantes A, van de Velde CJ. Gastriccancer: epidemiology, pathology and treatment.Ann Oncol 2003; 14 Suppl 2: ii31-ii36. 被引量：1
5Parkin DM. Global cancer statistics in the year 2000.Lancet Oncol 2001; 2: 533-543. 被引量：1
6Pisani P, Parkin DM, Bray F, Ferlay J. Erratum: Es-timates of the worldwide mortality from 25 cancersin 1990. Int. J. Cancer, 83, 18-29 (1999). Int J Cancer1999; 83: 870-873. 被引量：1
7Kampschder GH, Fujii A, Masuda Y. Gastric cancerdetected by mass survey. Comparison betweenmass survey and outpatient detection. Scand J Gas-troenterol 1989; 24: 813-817. 被引量：1
8Roder DM. The epidemiology of gastric cancer. Gas-tric Cancer 2002; 5 Suppl 1: 5-11. 被引量：1
9Layke JC, Lopez PP. Gastric cancer: diagnosisand treatment options. Am Fam Physician 2004; 69:1133-1140. 被引量：1
6Liu R R, Li M D, Li T, et al. Matrix metalloproteinase 2 (MMP2) protein expression and laryngeal cancer prognosis: ameta-analysis [J]. Int J Clin Exp Med, 2015, 8 (2):2261- 2266. 被引量：1
7Yu C, Zhou Y, Miao X, et al. Functionalhaplotypes in the promoter of matrixmetalloproteinase -2predictrisk of the occurrence and metastasis of esophagealcancer [ J ]. Cancer Res, 2004, 64(20) :7622-7628. 被引量：1
8Xu E, Lai M, Lv B, et al. A single nucleotide polymorphism in the matrix metalloproteinase-2 promoter is associated with colorectal cancer [ J ]. Biochem Biophys Res Commun, 2004, 324(3) :999-1003. 被引量：1
9Alakus H, Grass G, Hennecken JK, et al. Clinicopathological significance of MMP-2 and its specific inhibitor TIMP-2 in gastric cancer [ J ]. Histol Histopathol, 2008, 23 ( 8 ) : 917-923. 被引量：1
10Zhou Y, Yu C, Miao X, et al. Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility[J]. Carcinogenesis, 2005, 26(6): 1117-1121. 被引量：1
